We hope to take advantage of this over expression in NSCLC to achieve an optimized targeting of siRNA to NSCLC by conjugating anti-NTSR1-mAb to the surface of our hybrid nanoparticles. The gene discussed is NTSR1; the disease is non-small cell lung carcinoma.